Contract development and manufacturing organisation (CDMO) Samsung Biologics has been awarded the Gold Sustainability Rating from Corporate Social Responsibility (CSR) evaluator EcoVadis.
According to Samsung Biologics, the CDMO giant received a score of 71 out of 100, up 14 points from the silver rating it earned last year. The rating is based on performances in areas related to environment, labour and human rights, ethics and sustainable procurement.
The score ranks them among the top 5% of the more than 100,000 companies worldwide assessed by EcoVadis.
Samsung Biologics is a division of Samsung Group, the South Korean multinational manufacturing conglomerate most commonly known for its consumer and industry electronics business, which manufacturers devices such as mobile devices, televisions, and cameras.
The biologics division focuses on development and manufacturing services for the biopharmaceutical industry. Creating pharmaceutical drugs which are manufactured in, or created from biological sources, such as bacteria.
Founded in 2007 EcoVadis has grown to be one of the most reputable providers of business sustainability ratings, creating a global network of more than 100,000+ rated companies. This includes Epson and VMware who both published their ESG reports earlier this year.
“Achieving an EcoVadis Gold rating is further indication of Samsung Biologics’ strengthened ESG focus and our commitment to working with our suppliers and industry partners to reduce our environmental impact, integrate sustainable management, and build a more transparent, responsible value chain,” said Samsung Biologics CEO and president John Rim. “Not only is prioritising these efforts within our business the right thing to do, but it is also an important part of what we bring to our clients to help them meet their own sustainability commitments.”
The company recently published its annual ESG report, disclosing its environmental management strategy, outlining activities to reduce emissions. This included process energy optimisation, transitioning to renewable energy, and minimising the use of disposables in the manufacturing process through waste management and recycling.
Furthermore, Samsung Biologics’ second annual ESG report released in July highlighted a reduction in the company’s direct greenhouse gas emissions by 33% compared to 2021.
